Portfolio

Oxyrane

CEO Wouter Vervecken

Taking the bold steps needed to make the small ones possible.

Develops enzyme replacement therapies (ERT) for CNS manifestations of lysosomal storage diseases (LSDs).

By applying its proprietary robust and scalable glyco-engineering yeast platform, Oxyrane produces human lysosomal enzymes containing appropriate sugar structures, which enable superior product uptake and localization, resulting in greater efficacy at lower product doses.

Human Health

Oxyrane logo

UK

Suite 313, Piccadilly House, 49 Piccadilly
Manchester M1 2AP
United Kingdom

Industry

Biotech

Status

Past

Location

UK